Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 03, 2026

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

February 02, 2026

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

January 28, 2026

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27, 2026

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26, 2026

Tocilizumab Biosimilar CT-P47 Shows Promise for Rheumatoid Arthritis Self-Administration

June 19th 2025

By Cameron Santoro

Article

Tocilizumab biosimilar CT-P47, administered via autoinjector, offers comparable efficacy and a consistent safety profile to reference tocilizumab in patients with rheumatoid arthritis.

Strengthening Diabetes Care With Purpose-Built Data Infrastructure

June 18th 2025

By Skylar Jeremias

Article

Explore how real-world evidence and biosimilars enhance insulin access and adherence, improving diabetes care and outcomes for patients who have type 2 diabetes.

FDA Approves Steqeyma for Children With Plaque Psoriasis, Psoriatic Arthritis

June 17th 2025

By Skylar Jeremias

Article

Celltrion's FDA approval of Steqeyma enhances pediatric psoriasis treatment, offering flexible dosing options for children with chronic inflammatory conditions.

Eye on Pharma: Keytruda Biosimilar Deal; German Court Bans Imraldi; New Biosimilars for Japan

June 17th 2025

By Skylar Jeremias

Article

Alvotech and Dr. Reddy's partner to develop a Keytruda biosimilar, a German court bans Humira biosimilar over patent dispute, and Samsung Bioepis enters a strategic agreement with NIPRO Corporation in Japan.

New Data Support Hulio as an Interchangeable Adalimumab Option

June 16th 2025

By Skylar Jeremias

Article

The new data were collected to fulfill the FDA's requirements to designate adalimumab-fkjp (Hulio) as interchangeable with Humira, enhancing access to affordable biologics for chronic plaque psoriasis treatment.

Biosimilar Misconceptions, PBM Transparency, and Value-Based Care: Insights From Canavan & O'Dell

June 15th 2025

By Cameron Santoro

Video

Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, explain the misconception that cheaper biosimilars automatically lead to lower costs due to pharmacy benefit manager (PBM) spread pricing, while also highlighting major PBM trends toward increased transparency, value-based care, and efforts to reduce prescription costs.

High Acceptance Levels After Switching to an Adalimumab Biosimilar for IBD

June 14th 2025

By Deana Ferreri, PhD

Article

Patients with inflammatory bowel disease (IBD) show high acceptance of adalimumab biosimilars, achieving positive outcomes and clinical remission after switching.

The Top 5 Biosimilar Articles for the Week of June 9

June 13th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of June 9, 2025.

Biosimilar FYB202 Shows Therapeutic Equivalence to Ustekinumab for Plaque Psoriasis

June 12th 2025

By Cameron Santoro

Article

Switching from reference ustekinumab to biosimilar FYB202 maintained comparable efficacy, safety, and immunogenicity in patients with moderate to severe plaque psoriasis.

European Data Confirm Real-World Benefits of Adalimumab Biosimilars

June 11th 2025

By Skylar Jeremias

Article

New research highlights the efficacy and high patient satisfaction of adalimumab biosimilars in treating inflammatory diseases.